“Always important to have the ‘safe bets’ as well as the moonshots that exist under the surface.”
AVA6103 7+ months into clinic at this point; through 5 cohorts; across 6 indications; and backfilling with mandatory biopsies.
October was always a very important month for #AVCT.
Great discussion today at the @LongwoodLeaders forum in Boston on prioritizing the pipeline. Delighted to discuss the #AVCT pipeline & how we make hard decisions: sure bets v. Moonshots and those between. Big pharma and biotech have similar priority: patient impact
#LetsDoThis
TVR5 retweeted
Our CEO Christina Coughlin participating in the Prioritizing the Pipeline panel with @LongwoodLeaders in Boston today, discussing how we assess our platform opportunities to deliver high patient impact. #AVCT lnkd.in/p/ePwyn4yx
TVR5 retweeted
CEO Christina Coughlin and CFO Brian Hahn will be at @Jefferies Healthcare Conference, Nov 16-19 in London. Curious how pre|CISION® keeps potent payloads silent in the bloodstream and active in the tumor? Book a 1:1 via the partnering system. avacta.com/avacta-participat… #AVCT
Great insight into what went into getting #AVCT’s AVA6103 into the clinic in 14 months:
200+ PDCs synthesised
400+ compounds screened
40+ warheads evaluated
Also interesting the patent included x3 Sygnature Discovery inventors.
AVA6103 featured in a new case study this morning by #AVCT partner CRO Sygnature Discovery
sygnaturediscovery.com/case-…
#AVCT’s AVA6103 works.
“Mechanistically, the sustained release mechanism is playing out as we expect.”
“Findings increase confidence that the nonclinical-to-clinical translation is performing as intended - exactly as we anticipated.”
Watch episode 16 of our R&D Spotlight series, where Avacta Chief Executive Officer @coughlin582 takes a deep dive into the AVA6103 data presented at ESMO 2026. avacta.wistia.com/s/xs4ra3k8… #AVCT
TVR5 retweeted
The clinical data reading out of AVA6000 & 6103 is a product of Chris & her team’s execution.
These findings not only strengthen our platform, they validate our strategy of retaining IP until we believe it represents maximum value for #AVCT shareholders.
A busy Q4 ahead of us.
TVR5 retweeted
Hola! Greetings from Madrid 🇪🇸
Delighted to present updates in the AVA6000 program w/ efficacy in SGC. Platform data support our clinical observations with persistent FAP expression even in deep tumor response, with prolonge FAP activity and payload release. #AVCT
#LetsDoThis
New at #ESMO26: faridoxorubicin (AVA6000) data in salivary gland cancers show a median PFS of 11.4 months, with FAPI-PET imaging showing FAP persists as tumors respond. Poster 1549P, 12:00-12:45 PM CET.
avacta.com/faridoxorubicin-t…
#preCISION #AVCT
TVR5 retweeted
This was Ruairidh’s “wow moment” - lifting the lifetime doxorubicin limit for AVA6000 and allowing PFS as the primary endpoint, shortening the path to approval and the time it takes to get the drug to patients.
#AVCT
avacta.wistia.com/s/8pc1j0fx…
We look forward to #AVCT revealing its updated PFS in SGC and FAPI-PET imaging on Monday (26 Oct).
This PFS data has been maturing for some time and is the catalyst for dealing on AVA6000, given PFS will serve as the primary endpoint in the pivotal trial, as agreed by the FDA.
Avacta will present the most recent data analysis from the ongoing Phase 1a trial of Faridoxorubicin (AVA6000) and the design of the FOCUS-01 trial of FAP-Exd (AVA6103) in two poster presentations at the ESMO 2026 Congress. avacta.com/avacta-to-present… #AVCT
This is a critical thread to read in order to better understand #AVCT’s strategy.
Coughlin at BioXconomy this week.
#AVCT at BioXconomy:
Experience as a practicing oncologist brings 'different flavour' to CC's angle - 'if we do right by our patients we do right by our shareholders'
Spend is quite low in earlier stage programs and increases as you move through drug discovery
Thread 🧵